Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries MediciNova, Inc. - Common Stock (NQ: MNOV ) 2.070 +0.120 (+6.15%) Streaming Delayed Price Updated: 4:00 PM EST, Dec 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about MediciNova, Inc. - Common Stock < Previous 1 2 Next > MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND December 05, 2024 From MediciNova, Inc. Via GlobeNewswire MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders November 19, 2024 NIH-funded Phase 2-3 ALS Expanded Access study expands reach of MediciNova’s ongoing COMBAT-ALS trial and provides illustration of Company’s development strategy From MediciNova, Inc. Via GlobeNewswire MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver November 14, 2024 From MediciNova, Inc. Via GlobeNewswire MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis November 11, 2024 From MediciNova, Inc. Via GlobeNewswire MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium) October 23, 2024 From MediciNova, Inc. Via GlobeNewswire MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS) September 30, 2024 Academic group to receive a total of $22 million for the trial From MediciNova, Inc. Via GlobeNewswire MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND September 09, 2024 From MediciNova, Inc. Via GlobeNewswire MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting September 03, 2024 From MediciNova, Inc. Via GlobeNewswire MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition August 29, 2024 From MediciNova, Inc. Via GlobeNewswire MediciNova Chief Business Officer David H. Crean, Ph.D. Assumes Communications Role Overseeing Investor Engagement and Public Relations June 20, 2024 From MediciNova, Inc. Via GlobeNewswire MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer June 05, 2024 From MediciNova, Inc. Via GlobeNewswire MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024 June 03, 2024 From MediciNova, Inc. Via GlobeNewswire MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions May 28, 2024 From MediciNova, Inc. Via GlobeNewswire MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer May 20, 2024 From MediciNova, Inc. Via GlobeNewswire MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome May 14, 2024 From MediciNova, Inc. Via GlobeNewswire MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast) May 07, 2024 From MediciNova, Inc. Via GlobeNewswire MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO) April 02, 2024 From MediciNova, Inc. Via GlobeNewswire MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan March 26, 2024 From MediciNova, Inc. Via GlobeNewswire MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society March 20, 2024 From MediciNova, Inc. Via GlobeNewswire MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology March 12, 2024 From MediciNova, Inc. Via GlobeNewswire MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China January 17, 2024 From MediciNova, Inc. Via GlobeNewswire MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology December 21, 2023 From MediciNova, Inc. Via GlobeNewswire MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe December 06, 2023 From MediciNova, Inc. Via GlobeNewswire MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology November 19, 2023 From MediciNova, Inc. Via GlobeNewswire MediciNova’s Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria October 27, 2023 From MediciNova, Inc. Via GlobeNewswire MediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada October 10, 2023 From MediciNova, Inc. Via GlobeNewswire MediciNova Receives Gene Therapy Milestone Payment October 04, 2023 From MediciNova, Inc. Via GlobeNewswire MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury September 27, 2023 From MediciNova, Inc. Via GlobeNewswire MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology August 17, 2023 From MediciNova, Inc. Via GlobeNewswire MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Europe August 16, 2023 From MediciNova, Inc. Via GlobeNewswire < Previous 1 2 Next > Stock Quote API & Stock News API supplied by www.cloudquote.io Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
